Saturday 17 October 2026
Export DCOY’s income statement to Excel — free account
Decoy Therapeutics Inc
DCOY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.17
0.06
−4.88%
Follow DCOY
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 4 | 2 | — | — | — | — |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | 4.31 | 1.58 | (0.35) | — | 5,525,707.47 | 11,875,608.19 |
P/S ratio |
— | — | — | — | 5.92 | 2.50 | 3.93 | 0.00 | 43,395,293.79 | 0.00 |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 19.09 | 7.32 | (2.83) | (5.91) | (6.45) | 13.87 |
P/Operating CF |
— | — | — | — | (7.22) | (9.54) | (5.16) | 0.00 | (9,609,049.47) | (12,432,973.90) |
Beneish M-Score |
— | — | — | — | — | — | — | (5.61) | (4.13) | — |
P/B ratio |
— | — | — | — | 0.51 | 0.59 | 1.29 | 0.00 | 1,900,060.21 | 1,320,233.46 |
Price to Tangible BV |
— | — | — | — | 0.66 | 0.99 | 7.93 | 0.00 | 1,900,060.21 | 1,320,233.46 |
EV/Sales |
— | — | — | — | (2.74) | 0.47 | 3.06 | (3.14) | 43,395,267.64 | 0.00 |
EV/EBITDA |
— | — | — | — | 0.71 | 0.00 | 0.00 | 3.68 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | 0.89 | (0.24) | (0.92) | (1.47) | (1,994,896.84) | (2,443,295.60) |
EV/FCF |
— | — | — | — | 0.89 | (0.24) | (0.92) | (1.47) | (1,987,141.01) | (2,401,774.97) |
Quick Ratio |
2.07 | 1.61 | 4.54 | 3.22 | 13.84 | 6.69 | 1.13 | 0.78 | 5.70 | 15.71 |
Current Ratio |
2.13 | 1.98 | 5.02 | 3.40 | 14.29 | 7.06 | 1.42 | 0.81 | 5.91 | 16.06 |
Net Debt/EBITDA |
0.85 | 0.42 | 0.46 | 0.38 | 2.28 | 1.37 | 0.46 | 3.68 | 0.97 | 1.54 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.91% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.27 | 0.34 | 0.09 | 0.03 | 0.01 |
Operating CF/Net income |
0.39 | 0.81 | 1.02 | 0.56 | 0.80 | 1.33 | 1.67 | (2.33) | 0.81 | 0.81 |
Capex/Depreciation |
(80.14) | 0.00 | 0.00 | (223.88) | 0.00 | (0.14) | 0.00 | 0.28 | (0.42) | (1.89) |
| (338.31%) | (164.02%) | (160.07%) | (128.73%) | (41.94%) | (47.33%) | (149.01%) | (12.89%) | (77.88%) | (52.13%) | |
| (177.82%) | (116.05%) | (118.12%) | (113.93%) | (38.83%) | (39.91%) | (67.64%) | (8.62%) | (70.12%) | (49.90%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (84.22%) | (42.25%) | (75.50%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(213.70%) | (377.69%) | (240.26%) | (308.25%) | (45.50%) | (57.05%) | (493.23%) | 122.29% | (118.66%) | (66.79%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 268.94 | 0.00 | 1.85 | 2.98 | 4.41 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 464.54% | 132.11% | 115.99% | 65.98% | 1,333.06% | 2,016.25% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 331.74% | 116.67% | 222.54% | 120.34% | 1,451.84% | 1,964.58% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.36 | 0.64 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 30.38% | 0.00% | 21.69% | 1.59% | 331.05% | 650.34% |
Graham Net Nets |
— | — | — | — | 1.43 | 0.99 | 0.10 | 0.00 | 0.00 | 0.00 |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | (60.48%) | (60.43%) | (118.56%) | (78.78%) | 0.00% | 0.00% |
Free Cash Flow Yield |
— | — | — | — | (51.91%) | (78.66%) | (85.16%) | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 1,672.91 | 13,083.25 | 34,651.00 | 0.00 | 0.07 | 0.06 |
Operating CF per Share |
(49.76) | (56.43) | (5,585.26) | (11,730.20) | (9,272.91) | (25,778.50) | (115,801.00) | 0.00 | (1.61) | (1.97) |
Capex per Share |
(5.95) | 0.00 | 0.00 | (1,000.00) | 0.00 | (6.50) | 0.00 | 0.00 | (0.01) | (0.03) |
Free Cash Flow per Share |
(55.71) | (56.43) | (5,585.26) | (12,730.20) | (9,272.91) | (25,785.00) | (115,801.00) | 0.00 | (1.61) | (2.01) |
Cash per Share |
110.41 | 30.36 | 2,565.17 | 8,070.93 | 26,558.55 | 27,796.50 | 37,389.00 | 0.00 | 1.93 | 3.76 |
Shareholders Equity per Share |
60.71 | 18.85 | 2,298.83 | 6,923.07 | 35,202.73 | 55,398.00 | 105,809.00 | 0.00 | 1.69 | 3.65 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
60.71 | 18.85 | 2,298.83 | 6,923.07 | 35,202.73 | 55,398.00 | 105,809.00 | 0.00 | 1.69 | 3.65 |
Free Cash Flow |
(5.40) | (4.53) | (12.85) | (19.10) | (10.20) | (10.31) | (11.58) | 4.18 | (27.83) | (32.61) |
Working Capital |
5.82 | 1.48 | 5.22 | 10.25 | 28.05 | 13.56 | 1.38 | (1.50) | 28.69 | 58.58 |
Capital Expenditures |
(0.58) | — | — | (1.50) | — | 0.00 | — | 0.00 | (0.11) | (0.55) |
Net Current Asset Value |
5.82 | 1.48 | 5.22 | 10.25 | 28.05 | 13.02 | 1.38 | (1.50) | 28.65 | 58.57 |
EV/EBIT |
— | — | — | — | 0.71 | 0.00 | 0.00 | 3.64 | 0.00 | 0.00 |
Capex to Sales |
0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.55 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.18 | 0.00 | 0.00 | 0.00 | 2.43 | 0.80 | 5.10 | 0.45 | 0.77 | 0.53 |
Cash ROIC |
(32.56%) | (114.67%) | (114.83%) | (84.90%) | (15.01%) | (30.56%) | (80.87%) | 86.04% | (44.58%) | (27.08%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 2.71 | 0.00 | 192.26 | 112.79 | 89.44 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.32 | 0.64 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 1.14 | 1.50 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,444.43 | 656.64 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | 0.00 | 158.35 | 311.24 | 250.11 |
Average Receivables |
— | — | — | 2.73 | — | 1.93 | — | 0.01 | 0.01 | 0.01 |
Average Payables |
0.94 | 0.77 | 1.73 | 2.20 | 1.70 | 1.82 | 1.09 | 1.19 | 1.60 | 1.03 |
Average Inventory |
— | — | — | — | — | — | 0.09 | 0.31 | 0.44 | 0.44 |
Average Assets |
7.04 | 4.80 | 10.62 | 27.74 | 32.88 | 19.41 | 10.25 | 20.80 | 49.10 | 79.14 |
Average Common Equity |
3.70 | 3.40 | 7.84 | 24.55 | 30.44 | 16.37 | 4.65 | 13.92 | 44.21 | 75.75 |
Columns are period end dates